MIAMI, Jan. 04, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC:EHVVF) (the “Company”), a leader in digital therapeutics and developer of KetaDASH, a home delivery platform for patients who have been prescribed Ketamine infusions, announced today the Company has applied to OTC Markets to uplist its shares to the OTCQB. The OTCQB offers transparent trading in entrepreneurial and development stage companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process. These standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.
Ehave has also applied to list its shares on the Canadian Securities Exchange (CSE). The CSE began operations in 2003 and is based in Toronto, Canada. In order to list on the CSE companies must demonstrate that they have liquid assets, or have a viable plan to show they can sustain their operations and achieve their goals. The CSE also requires any company that has not started generating revenue must have a plan outlining how it will develop its business and have the financial resources to carry it out.
Ehave CEO Ben Kaplan said, “Ehave uplisting to the OTCQB and applying for listing on the CSE is a tremendous milestone for our company and exhibits our continued commitment to our shareholders. We believe listing on the OTCQB will provide the Company with increased access to US institutional and retail investors and a broader shareholder base. A CSE listing will provide Ehave and its shareholders and opportunity to introduce our Company to an entirely new investment audience." Mr. Kaplan continued, "I would like to take this opportunity to wish all of our shareholders a happy and prosperous New Year."
Additional Ehave Inc. Information
We are truly grateful for the support of EHVVF shareholders! Please …